Skip to Content

Synarel (nafarelin) Disease Interactions

There are 4 disease interactions with Synarel (nafarelin):

Major

Nafarelin nasal (applies to Synarel) abnormal vaginal bleeding

Major Potential Hazard, High plausibility. Applicable conditions: Abnormal Uterine Bleeding

The use of nafarelin nasal is contraindicated in patients with undiagnosed, abnormal vaginal bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present.

References

  1. "Product Information. Synarel Nasel Solution (nafarelin nasal)." Searle, Chicago, IL.
Moderate

Nafarelin (applies to Synarel) seizures

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Brain/Intracranial Tumor, Cerebral Vascular Disorder

Postmarketing reports of convulsions have been observed in patients receiving GnRH agonists. These have included patients with a history of seizures, epilepsy, cerebrovascular disorder, central nervous anomalies such as tumors, and patients receiving concomitant medications that have been associated with convulsions. Convulsions have also been reported in patients with none of these conditions. Caution is advised when administering nafarelin to patients with any of these conditions.

Moderate

Nafarelin nasal (applies to Synarel) bone density loss

Moderate Potential Hazard, High plausibility. Applicable conditions: Osteoporosis, Alcoholism

Nafarelin induces a hypoestrogenic effect that results in a small loss in bone density. Therapy with nafarelin should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).

References

  1. "Product Information. Synarel Nasel Solution (nafarelin nasal)." Searle, Chicago, IL.
Moderate

Nafarelin nasal (applies to Synarel) ovarian cysts

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Adrenal Tumor

Nafarelin therapy induces a release of pituitary gonadotropins (LH and FSH). Ovarian cysts or enlargement of existing ovarian cysts (primarily in women with polycystic ovarian disease) have been reported during the first months of treatment. Spontaneous resolution generally occurs in 4 to 6 weeks of therapy, but some cases require discontinuation of nafarelin therapy.

References

  1. "Product Information. Synarel Nasel Solution (nafarelin nasal)." Searle, Chicago, IL.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.